Sunovion Answers

Sunovion Answers

Need support? Ask Sunovion Answers for information about LONHALA MAGNAIR

Our Sunovion Answers team of support specialists can assist you and your patients with questions on insurance coverage, co-pay costs, and available resources. Specialists are available between 8 AM and 8 PM ET, Monday through Friday.

Sunovion Answers is a patient support service that can answer product and reimbursement questions about LONHALA MAGNAIR, and provide resources on COPD. Offerings include:

  • Reimbursement and financial assistance
  • Prior authorization assistance
  • Product information about LONHALA MAGNAIR
  • COPD resources and support group information

1-844-276-8262
8 AM – 8 PM ET, MONDAY – FRIDAY

Comprehensive support throughout treatment

Patient support services will be available at participating pharmacies. If the following treatment services are not offered by your patient's pharmacy, they can contact Sunovion Answers toll-free at 1-844-276-8262 to find out how to get access.

Treatment initiation for COPD Patients and LONHALA MAGNAIR resources

Treatment Initiation

  • Disease and device education
  • LONHALA MAGNAIR education resources
  • Training offered by participating pharmacies
 

Follow-up support throughout treatment

Follow-up

  • Device education
  • Refill reminder call
  • Maintenance check-ins
 

COPD=chronic obstructive pulmonary disease.

Important Safety Information & Indication

Important Safety Information
 

LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, LONHALA MAGNAIR can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with LONHALA MAGNAIR, it should be treated immediately with an inhaled, short-acting bronchodilator; LONHALA MAGNAIR should be discontinued immediately and alternative therapy instituted.

Immediate hypersensitivity reactions have been reported with LONHALA MAGNAIR. If signs occur, discontinue LONHALA MAGNAIR immediately and institute alternative therapy.

LONHALA MAGNAIR should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.

The most common adverse events reported in ≥2% of patients taking LONHALA MAGNAIR, and occurring more frequently than in patients taking placebo, were dyspnea (4.9% vs 3.0%) and urinary tract infection (2.1% vs 1.4%).

LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see full Prescribing Information and Patient Information for LONHALA MAGNAIR at www.sunovionprofile.com/lonhala-magnair.

Indication
 

LONHALA™ MAGNAIR™ (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.